Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Cooperative Group of Study and Treatment of Breast Cancer.
Riccardi A, Brugnatelli S, Giordano M, Danova M, Pugliese P, Tinelli C, Klersy C, Richetti A, Fava S, Nastasi G, Rinaldi E, Fregoni V, De Monte A, Trotti G, Bovio A, Ascari E. Riccardi A, et al. Tumori. 1998 Sep-Oct;84(5):540-6. doi: 10.1177/030089169808400506. Tumori. 1998. PMID: 9862513 Clinical Trial.
Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.
Riccardi A, Tinelli C, Brugnatelli S, Pugliese P, Giardina V, Giordano M, Danova M, Richetti A, Fava S, Rinaldi E, Fregoni V, Trotti G, Poli A. Riccardi A, et al. Int J Oncol. 2000 Apr;16(4):769-76. doi: 10.3892/ijo.16.4.769. Int J Oncol. 2000. PMID: 10717247 Clinical Trial.
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
Riccardi A, Pugliese P, Danova M, Brugnatelli S, Grasso D, Giordano M, Bernardo G, Giardina G, Fava S, Montanari G, Pedrotti C, Trotti G, Rinaldi E, Poli MA, Tinelli C. Riccardi A, et al. Br J Cancer. 2001 Jul 20;85(2):141-6. doi: 10.1054/bjoc.2001.1897. Br J Cancer. 2001. PMID: 11461067 Free PMC article. Clinical Trial.
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol.
Riccardi A, Mora O, Tinelli C, Porta C, Danova M, Brugnatelli S, Grasso D, Tolcà B, Spanedda R, De Paoli A, Barbarano L, Cavanna L, Giordano M, Delfini C, Nicoletti G, Bergonzi C, Rinaldi E, Piccinini L, Ascari E. Riccardi A, et al. Eur J Cancer. 2003 Jan;39(1):31-7. doi: 10.1016/s0959-8049(02)00529-4. Eur J Cancer. 2003. PMID: 12504655 Clinical Trial.
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
Brugnatelli S, Riccardi A, Ucci G, Mora O, Barbarano L, Piva N, Piccinini L, Bergonzi C, De Paoli A, Di Stasi M, Rinaldi E, Trotti G, Petrini M, Ascari E. Brugnatelli S, et al. Among authors: riccardi a. Br J Cancer. 1996 Mar;73(6):794-7. doi: 10.1038/bjc.1996.138. Br J Cancer. 1996. PMID: 8611382 Free PMC article. Clinical Trial.
384 results